Clinical Trial Update: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder [Phase 2]

View source ↗

Summary

A Phase 2 crossover trial evaluating L1-79 for autism in youths aged 12-21 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• L1-79

Snippet

Sponsor: Yamo Pharmaceuticals LLC | Conditions: Autism Spectrum Disorder, Autism | Phase 2 | Status: COMPLETED